Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages.
Permissiveness of monocytes and macrophages to human immunodeficiency virus (HIV) infection is modulated by various stimuli. In this study we demonstrate that stimulation of primary monocytes and monocyte-derived macrophages (MDM) through the receptors for the Fc portion of immunoglobulin G (IgG) (FcgammaR) inhibits HIV type 1 (HIV-1) replication. Viral p24 production was decreased by 1.5 to 3 log units in MDM infected with both R5 and X4 HIV-1 strains upon stimulation by immobilized IgG but not upon stimulation by soluble IgG or by F(ab')(2) IgG fragments. Although MDM activation by immobilized IgG induced high levels of macrophage-derived chemokine secretion as well as a sustained down-regulation of CD4 and a transient decrease in CCR5 expression, these factors did not appear to play a major role in the suppression of HIV-1 replication. Single-cycle infection of FcgammaR-stimulated MDM with HIV-1 virions pseudotyped with either HIV-1 R5 or vesicular stomatitis virus G envelopes was inhibited, suggesting a postentry restriction of viral replication. PCR analyses of HIV-1 DNA intermediate replication forms suggested that reverse transcription is not affected by stimulation with immobilized human IgG, at least during the first replication cycle. The accumulation of PCR products corresponding to nuclear unintegrated two-long-terminal-repeat circles and the relative decrease of integrated HIV-1 DNA signals suggest an inhibition of proviral integration. Our data, showing that FcgammaR-mediated activation of MDM is a potent mechanism of HIV-1 suppression, raise the possibility that FcgammaR cross-linking by immune complexes may contribute to the control of viral replication in macrophages.
Perez-Bercoff
Danielle
D
Unité de Biologie des Rétrovirus, Institut Pasteur, 75725 Paris Cedex 15, France.
David
Annie
A
Sudry
Hugues
H
Barré-Sinoussi
Françoise
F
Pancino
Gianfranco
G
D021581:Active Transport, Cell Nucleus; D001483:Base Sequence; D015704:CD4 Antigens / Q000378:metabolism; D003432:Cross-Linking Reagents; D016207:Cytokines / Q000096:biosynthesis; D004279:DNA, Viral / Q000235:genetics / Q000378:metabolism; D015752:Genes, env; D016655:HIV Core Protein p24 / Q000096:biosynthesis; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000502:physiology*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology / Q000821:virology; D008562:Membrane Glycoproteins / Q000235:genetics; D009000:Monocytes / Q000276:immunology / Q000821:virology; D011533:Proviruses / Q000235:genetics / Q000276:immunology; D019713:Receptors, CCR5 / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism*; D014759:Viral Envelope Proteins / Q000235:genetics; D016662:Virus Integration / Q000276:immunology; D014779:Virus Replication / Q000276:immunology*
D015704:CD4 Antigens; D003432:Cross-Linking Reagents; D016207:Cytokines; D004279:DNA, Viral; C028391:G protein, vesicular stomatitis virus; D016655:HIV Core Protein p24; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D019713:Receptors, CCR5; D017452:Receptors, IgG; D014759:Viral Envelope Proteins